Belite Bio Initiates New Drug Application Submission
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy BLTE?
Belite Bio announced that it has initiated a rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for tinlarebant, an investigational novel oral therapy for the treatment of Stargardt disease type 1, a rare, inherited retinal disorder caused by mutations in the ABCA4 gene. Tinlarebant has previously been granted Breakthrough Therapy Designation by the FDA for STGD1, and the FDA has previously granted Belite approval for the rolling submission of the NDA. The Company expects to complete the NDA rolling submission in the second quarter of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLTE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLTE
Wall Street analysts forecast BLTE stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 161.260
Low
154.00
Averages
186.57
High
200.00
Current: 161.260
Low
154.00
Averages
186.57
High
200.00
About BLTE
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Deutsche Bank to Host Depositary Receipts Investor Conference
- Conference Details: Deutsche Bank is set to host the Depositary Receipts Virtual Investor Conference on April 28, 2026, featuring live presentations from international companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands, and France, aimed at attracting a diverse range of investors and analysts.
- Participating Companies: The agenda includes presentations from Lotus Technology Inc., Viomi Technology Co., Ltd, and Belite Bio, Inc., showcasing Deutsche Bank's expertise in managing cross-border equity structures, which is expected to enhance its influence in the global market.
- Participation Fee: The conference is free for participants, with pre-registration suggested, reflecting Deutsche Bank's commitment to providing convenient services for investors and further solidifying its leadership in investor relations management.
- Service Range: Deutsche Bank specializes not only in the administration of depositary receipts but also offers a wide array of financial services, including complex securitizations, project financing, and debt restructuring, demonstrating its comprehensive strength in the global financial services market.
See More
Belite Bio to Present at Investor Conference
- New Drug Application Progress: Belite Bio initiated the rolling submission of a New Drug Application for tinlarebant targeting Stargardt disease type 1 on April 21, 2026, following Phase 3 DRAGON trial results showing a 35.7% reduction in retinal lesion growth, which not only offers new hope for patients but also enhances the company's competitiveness in the ophthalmic drug market.
- Clinical Trial Update: The company has completed enrollment in the Phase 2/3 DRAGON II trial for Stargardt disease type 1, marking a significant advancement in the clinical development of tinlarebant, which is expected to lay the groundwork for future market launch.
- Successful Financing: Belite Bio completed a $402 million underwritten public offering, with funds allocated for the commercialization of tinlarebant and pipeline expansion, a move that not only strengthens the company's financial position but also provides ample funding for future R&D efforts.
- Investor Conference Arrangement: Chief Medical Officer Dr. Hendrick Scholl will present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28, 2026, which is expected to attract investor attention and enhance the company's visibility in the capital markets.
See More
Belite Bio to Present at Virtual Investor Conference
- New Drug Application Progress: Belite Bio initiated the New Drug Application for tinlarebant targeting Stargardt disease type 1 on April 21, 2026, following Phase 3 DRAGON trial results that showed a 35.7% reduction in retinal lesion growth, establishing a significant breakthrough in treatment.
- Clinical Trial Enrollment Completed: The company has completed enrollment in the Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a crucial milestone in its clinical development process, which is expected to drive subsequent market launch efforts.
- Successful Financing: Belite Bio completed a $402 million underwritten public offering, providing essential funding for the commercialization of tinlarebant and pipeline expansion, thereby strengthening its position in the competitive biopharmaceutical market.
- Investor Conference Participation: Chief Medical Officer Dr. Hendrick Scholl will present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28, 2026, offering real-time interactive Q&A opportunities, which will enhance the company's communication efficiency with investors.
See More
Belite Bio Initiates NDA Submission for Tinlarebant to Treat Stargardt Disease
- NDA Submission Initiated: Belite Bio Inc. announced the initiation of a rolling NDA submission to the FDA for Tinlarebant, aimed at treating the rare Stargardt disease, marking a significant advancement in the company's ophthalmic drug development.
- Disease Background: Stargardt disease is a hereditary retinal disorder caused by mutations in the ABCA4 gene, typically manifesting in adolescence and leading to progressive retinal degeneration, which severely impacts patients' vision and quality of life.
- Drug Mechanism: Tinlarebant works by reducing and maintaining serum retinol-binding protein 4 (RBP4) levels, thereby regulating the formation of bisretinoids and effectively preventing disease progression, showcasing its potential in treating STGD1.
- Clinical Trial Progress: The drug is currently undergoing Phase 2/3 DRAGON II trials for adolescent STGD1 patients and is expected to complete the rolling NDA submission by the second quarter of 2026, further advancing its path to market.
See More
Insider at Belite Bio (BLTE.US) Plans to Sell $24.31 Million in Common Stock via Form 144
Stock Sale Announcement: Yu-Hsin Lin intends to sell 136,000 shares of its common stock on April 9.
Market Value: The total market value of the shares being sold is approximately $24.31 million.
See More
Insider at Belite Bio (BLTE.US) Plans to Sell $17.87 Million in Common Stock via Form 144
Company Announcement: Haoyuan Chuang intends to sell 100,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $17.8 million.
See More
Deutsche Bank to Host Depositary Receipts Investor Conference
- Conference Details: Deutsche Bank is set to host the Depositary Receipts Virtual Investor Conference on April 28, 2026, featuring live presentations from international companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands, and France, aimed at attracting a diverse range of investors and analysts.
- Participating Companies: The agenda includes presentations from Lotus Technology Inc., Viomi Technology Co., Ltd, and Belite Bio, Inc., showcasing Deutsche Bank's expertise in managing cross-border equity structures, which is expected to enhance its influence in the global market.
- Participation Fee: The conference is free for participants, with pre-registration suggested, reflecting Deutsche Bank's commitment to providing convenient services for investors and further solidifying its leadership in investor relations management.
- Service Range: Deutsche Bank specializes not only in the administration of depositary receipts but also offers a wide array of financial services, including complex securitizations, project financing, and debt restructuring, demonstrating its comprehensive strength in the global financial services market.
See More
Belite Bio to Present at Investor Conference
- New Drug Application Progress: Belite Bio initiated the rolling submission of a New Drug Application for tinlarebant targeting Stargardt disease type 1 on April 21, 2026, following Phase 3 DRAGON trial results showing a 35.7% reduction in retinal lesion growth, which not only offers new hope for patients but also enhances the company's competitiveness in the ophthalmic drug market.
- Clinical Trial Update: The company has completed enrollment in the Phase 2/3 DRAGON II trial for Stargardt disease type 1, marking a significant advancement in the clinical development of tinlarebant, which is expected to lay the groundwork for future market launch.
- Successful Financing: Belite Bio completed a $402 million underwritten public offering, with funds allocated for the commercialization of tinlarebant and pipeline expansion, a move that not only strengthens the company's financial position but also provides ample funding for future R&D efforts.
- Investor Conference Arrangement: Chief Medical Officer Dr. Hendrick Scholl will present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28, 2026, which is expected to attract investor attention and enhance the company's visibility in the capital markets.
See More
Belite Bio to Present at Virtual Investor Conference
- New Drug Application Progress: Belite Bio initiated the New Drug Application for tinlarebant targeting Stargardt disease type 1 on April 21, 2026, following Phase 3 DRAGON trial results that showed a 35.7% reduction in retinal lesion growth, establishing a significant breakthrough in treatment.
- Clinical Trial Enrollment Completed: The company has completed enrollment in the Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a crucial milestone in its clinical development process, which is expected to drive subsequent market launch efforts.
- Successful Financing: Belite Bio completed a $402 million underwritten public offering, providing essential funding for the commercialization of tinlarebant and pipeline expansion, thereby strengthening its position in the competitive biopharmaceutical market.
- Investor Conference Participation: Chief Medical Officer Dr. Hendrick Scholl will present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28, 2026, offering real-time interactive Q&A opportunities, which will enhance the company's communication efficiency with investors.
See More
Belite Bio Initiates NDA Submission for Tinlarebant to Treat Stargardt Disease
- NDA Submission Initiated: Belite Bio Inc. announced the initiation of a rolling NDA submission to the FDA for Tinlarebant, aimed at treating the rare Stargardt disease, marking a significant advancement in the company's ophthalmic drug development.
- Disease Background: Stargardt disease is a hereditary retinal disorder caused by mutations in the ABCA4 gene, typically manifesting in adolescence and leading to progressive retinal degeneration, which severely impacts patients' vision and quality of life.
- Drug Mechanism: Tinlarebant works by reducing and maintaining serum retinol-binding protein 4 (RBP4) levels, thereby regulating the formation of bisretinoids and effectively preventing disease progression, showcasing its potential in treating STGD1.
- Clinical Trial Progress: The drug is currently undergoing Phase 2/3 DRAGON II trials for adolescent STGD1 patients and is expected to complete the rolling NDA submission by the second quarter of 2026, further advancing its path to market.
See More
Insider at Belite Bio (BLTE.US) Plans to Sell $24.31 Million in Common Stock via Form 144
Stock Sale Announcement: Yu-Hsin Lin intends to sell 136,000 shares of its common stock on April 9.
Market Value: The total market value of the shares being sold is approximately $24.31 million.
See More
Insider at Belite Bio (BLTE.US) Plans to Sell $17.87 Million in Common Stock via Form 144
Company Announcement: Haoyuan Chuang intends to sell 100,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $17.8 million.
See More
